2015年中国肺癌新发病例73．3万，死亡病例61．0万。发病率和死亡率均居恶性肿瘤的首位。80％多的肺癌患者为非小细胞肺癌（non-small cell lung cancer ,NSCLC），70％左右的患者数就诊时已属晚期，失去了手术治疗的机会。化疗是晚期NS...2015年中国肺癌新发病例73．3万，死亡病例61．0万。发病率和死亡率均居恶性肿瘤的首位。80％多的肺癌患者为非小细胞肺癌（non-small cell lung cancer ,NSCLC），70％左右的患者数就诊时已属晚期，失去了手术治疗的机会。化疗是晚期NSCLC治疗的主要手段，其地位虽然没有发生根本的动摇，但其疗效已达到平台，同时化疗的毒副反应也限制了其广泛的临床应用。展开更多
Liver cancer is a common malignant tumor in China and a major health concern. We aimed to estimate the liver cancer incidence and mortality in China in 2010 using liver cancer data from some Chinese cancer registries ...Liver cancer is a common malignant tumor in China and a major health concern. We aimed to estimate the liver cancer incidence and mortality in China in 2010 using liver cancer data from some Chinese cancer registries and provide reference for liver cancer prevention and treatment. We collected and evaluated the incidence and mortality data of liver cancer in 2010 from 145 cancer registries, which were included in the 2013 Chinese Cancer Registry Annual Report, calculated crude, standardized, and truncated incidences and mortalities, and estimated new liver cancer cases and deaths from liver cancer throughout China and in different regions in 2010 from Chinese practical population. The estimates of new liver cancer cases and deaths were 358,840 and 312,432, respectively, in China in 2010. The crude incidence, age-standardized rate by Chinese standard population(ASR China), and age-standardized rate by world standard population(ASR world) were 27.29/100,000, 21.35/100,000, and 20.87/100,000, respectively; the crude, ASR China, and ASR world mortalities were 23.76/100,000, 18.43/100,000, and 18.04/100,000, respectively. The incidence and mortality were the highest in western regions, higher in rural areas than in urban areas, and higher in males than in females. The age-specific incidence and mortality of liver cancer showed a rapid increase from age 30 and peaked at age 80-84 or 85+. Our results indicated that the 2010 incidence and mortality of liver cancer in China, especially in undeveloped rural areas and western regions, were among high levels worldwide. The strategy for liver cancer prevention and treatment should be strengthened.展开更多
文摘2015年中国肺癌新发病例73．3万，死亡病例61．0万。发病率和死亡率均居恶性肿瘤的首位。80％多的肺癌患者为非小细胞肺癌（non-small cell lung cancer ,NSCLC），70％左右的患者数就诊时已属晚期，失去了手术治疗的机会。化疗是晚期NSCLC治疗的主要手段，其地位虽然没有发生根本的动摇，但其疗效已达到平台，同时化疗的毒副反应也限制了其广泛的临床应用。
基金supported by the Chinese National Twelveth Five-year Program for Science and Technology Development (No. 2012ZX10002010)
文摘Liver cancer is a common malignant tumor in China and a major health concern. We aimed to estimate the liver cancer incidence and mortality in China in 2010 using liver cancer data from some Chinese cancer registries and provide reference for liver cancer prevention and treatment. We collected and evaluated the incidence and mortality data of liver cancer in 2010 from 145 cancer registries, which were included in the 2013 Chinese Cancer Registry Annual Report, calculated crude, standardized, and truncated incidences and mortalities, and estimated new liver cancer cases and deaths from liver cancer throughout China and in different regions in 2010 from Chinese practical population. The estimates of new liver cancer cases and deaths were 358,840 and 312,432, respectively, in China in 2010. The crude incidence, age-standardized rate by Chinese standard population(ASR China), and age-standardized rate by world standard population(ASR world) were 27.29/100,000, 21.35/100,000, and 20.87/100,000, respectively; the crude, ASR China, and ASR world mortalities were 23.76/100,000, 18.43/100,000, and 18.04/100,000, respectively. The incidence and mortality were the highest in western regions, higher in rural areas than in urban areas, and higher in males than in females. The age-specific incidence and mortality of liver cancer showed a rapid increase from age 30 and peaked at age 80-84 or 85+. Our results indicated that the 2010 incidence and mortality of liver cancer in China, especially in undeveloped rural areas and western regions, were among high levels worldwide. The strategy for liver cancer prevention and treatment should be strengthened.
